Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials

Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials

Abstract Background In addition to the increased risk for cardiovascular (CV) disease and CV events associated with migraine, patients with migraine can also present with a number of CV risk factors (CVRFs). Existing treatment options can be limited due to contraindications, increased burden associa...

Full description

Bibliographic Details
Main Authors: Robert E. Shapiro, Helen M. Hochstetler, Ellen B. Dennehy, Rashna Khanna, Erin Gautier Doty, Paul H. Berg, Amaal J. Starling
Format: Article
Language:English
Published: BMC 2019-08-01
Series:The Journal of Headache and Pain
Subjects:
Migraine
Cardiovascular disease
Lasmiditan
Safety
Ditan
Online Access:http://link.springer.com/article/10.1186/s10194-019-1044-6

Internet

http://link.springer.com/article/10.1186/s10194-019-1044-6

Similar Items